Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Brookstone Capital Management

Brookstone Capital Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 158.4% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,752 shares of the medical research company's stock after purchasing an additional 30,500 shares during the quarter. Brookstone Capital Management's holdings in Amgen were worth $15,500,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the company. Global Wealth Management Investment Advisory Inc. lifted its stake in Amgen by 23.0% during the 1st quarter. Global Wealth Management Investment Advisory Inc. now owns 8,448 shares of the medical research company's stock valued at $2,632,000 after acquiring an additional 1,581 shares during the period. Huntleigh Advisors Inc. raised its holdings in shares of Amgen by 2.0% during the first quarter. Huntleigh Advisors Inc. now owns 9,542 shares of the medical research company's stock worth $2,973,000 after purchasing an additional 184 shares during the last quarter. Pacific Heights Asset Management LLC lifted its position in Amgen by 1.7% during the first quarter. Pacific Heights Asset Management LLC now owns 59,000 shares of the medical research company's stock valued at $18,381,000 after purchasing an additional 1,000 shares during the period. IFM Investors Pty Ltd lifted its position in Amgen by 8.9% during the first quarter. IFM Investors Pty Ltd now owns 111,679 shares of the medical research company's stock valued at $35,984,000 after purchasing an additional 9,141 shares during the period. Finally, GF Fund Management CO. LTD. boosted its holdings in Amgen by 2.7% in the first quarter. GF Fund Management CO. LTD. now owns 125,019 shares of the medical research company's stock valued at $38,950,000 after purchasing an additional 3,237 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Up 0.5%

AMGN opened at $298.25 on Friday. The company has a market cap of $160.37 billion, a PE ratio of 27.21, a price-to-earnings-growth ratio of 2.68 and a beta of 0.49. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a 50-day moving average price of $282.12 and a 200 day moving average price of $286.57. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. Amgen had a return on equity of 176.11% and a net margin of 17.39%. Amgen's quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the business earned $3.96 EPS. Sell-side analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on AMGN shares. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 18th. Piper Sandler reiterated an "overweight" rating and set a $328.00 price target on shares of Amgen in a research report on Friday, June 27th. Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price target on shares of Amgen in a report on Tuesday, June 24th. Morgan Stanley restated an "equal weight" rating on shares of Amgen in a research report on Friday, May 2nd. Finally, Erste Group Bank lowered shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $307.82.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the transaction, the senior vice president owned 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.76% of the company's stock.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.